Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBT (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of EBT data on record, last reported at -$26.7 million in Q3 2025.

  • For Q3 2025, EBT rose 33.58% year-over-year to -$26.7 million; the TTM value through Sep 2025 reached -$149.5 million, up 16.51%, while the annual FY2024 figure was -$165.7 million, 40.16% up from the prior year.
  • EBT reached -$26.7 million in Q3 2025 per ZNTL's latest filing, up from -$26.9 million in the prior quarter.
  • Across five years, EBT topped out at $10.2 million in Q1 2024 and bottomed at -$99.5 million in Q2 2023.
  • Average EBT over 4 years is -$51.0 million, with a median of -$52.3 million recorded in 2022.
  • Peak YoY movement for EBT: soared 116.74% in 2024, then tumbled 574.11% in 2025.
  • A 4-year view of EBT shows it stood at -$48.5 million in 2022, then fell by 25.87% to -$61.1 million in 2023, then grew by 21.94% to -$47.7 million in 2024, then soared by 44.02% to -$26.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$26.7 million in Q3 2025, -$26.9 million in Q2 2025, and -$48.3 million in Q1 2025.